Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01524978 · ClinicalTrials.gov registry record · Phase 2
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
A Phase 2 study of Multiple Myeloma, Neoplasms, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
- 20
- Study locations
NCT01524978 is a Phase 2 study of Multiple Myeloma, Neoplasms that has completed, run by Hoffmann-La Roche. The registered enrollment target is 208 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT01524978, a Phase 2 study of Multiple Myeloma, Neoplasms, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
- 20
- Study locations
Study Summary
This open-label, multi-center study will assess the efficacy and safety of vemurafenib in participants with BRAF V600 mutation-positive cancers (solid tumors and multiple myeloma, except melanoma and papillary thyroid cancer) and for whom vemurafenib is deemed the best treatment option in the opinion of the investigator. Participants will receive twice daily oral doses of 960 mg vemurafenib until disease progression, unacceptable toxicity, or withdrawal of consent. The safety and efficacy of vemurafenib in combination with cetuximab in a subset of participants with colorectal cancer will also be assessed.
Conditions Studied
Interventions
- DRUG cetuximab
- DRUG vemurafenib
Study Locations (20)
Other
- Tianjin Cancer Hospital - Tianjin
- Institut Bergonie; Oncologie - Bordeaux
- Centre Francois Baclesse; Oncologie - Caen
- Centre Georges François Leclerc - Dijon
- Centre Leon Berard; Departement Oncologie Medicale - Lyon
- Institut Paoli-Calmettes; Oncologie Medicale 1 - Marseille
- Centre Rene Gauducheau - Saint-Herblain
- Institut Claudius Regaud; Departement Oncologie Medicale - Toulouse
- Institut Gustave Roussy; Sitep - Villejuif
Massachusetts
- Massachusetts General Hospital;Oncology - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Arizona
- Arizona Oncology - Tucson
Colorado
- Rocky Mountain Cancer Centers, LLP - Aurora
Michigan
- Karmanos Cancer Institute - Detroit
Missouri
- Washington University - St Louis
New York
- Memorial Sloan-Kettering Cancer Center - New York
Tennessee
- Vanderbilt - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2012-04-12 |
| Est. Completion | 2016-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01524978
The ClinicalTrials.gov registry entry for NCT01524978 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma, Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which cetuximab is the first listed.
NCT01524978 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT01524978 about?
NCT01524978 is a clinical study titled "A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers". This open-label, multi-center study will assess the efficacy and safety of vemurafenib in participants with BRAF V600 mutation-positive cancers (solid tumors and multiple myeloma, except melanoma and papillary thyroid cancer) and for whom vemurafenib is deemed the best treatment option in the opinio...
What is the current status of trial NCT01524978?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2012-04-12. Estimated completion is 2016-10-28.
What conditions does trial NCT01524978 study?
This clinical trial studies the following conditions: Multiple Myeloma, Neoplasms.
What interventions are being tested in trial NCT01524978?
The interventions under investigation include: cetuximab (DRUG), vemurafenib (DRUG).
Who is sponsoring clinical trial NCT01524978?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01524978 being conducted?
This trial has 20 study locations across Arizona, Colorado, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma, Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.